More recently, Ryall et al., by studying the clinical outcome of more than 1000 PLGGs, confirmed the poor outcome of BRAF-mutant gliomas and proposed a molecular-based risk stratification pushing forward BRAF p.V600E gliomas into the intermediate- and high-risk subgroups [8]. This evidence concerns the gene BRAF and central nervous system cancer.